---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Drug interactions questions"
description: "Drug interactions questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is the Imbruvica dose with CYP3A inhibitors like voriconazole or posaconazole? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Drug interactions questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Drug interactions questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications: Drug interactions](https://www.evicenter.com/medical-information/imbruvica/drug-interactions).

## Drug interactions

<a id="imbruvica-cyp3a-inhibitor-dose"></a>

### What is the Imbruvica dose with CYP3A inhibitors like voriconazole or posaconazole?

> “IMBRUVICA<sup>®</sup> dose modifications for CYP3A inhibitors in B-cell malignancies*
> Coadministered Drug	Recommended IMBRUVICA<sup>®</sup> Dose
> Moderate CYP3A inhibitor<sup>†</sup>	
>
> 280 mg once daily
>
> Modify dose as recommended per Section 2.2 of the full Prescribing Information
>
>
>
>
> Voriconazole 200 mg twice daily
>
> Posaconazole suspension 100 mg once daily, 100 mg twice daily, or 200 mg twice daily
>
>
>
> 140 mg once daily
>
> Modify dose as recommended per Section 2.2 of the full Prescribing Information
>
>
>
>
> Posaconazole suspension 200 mg three times daily or 400 mg twice daily
>
> Posaconazole intravenously 300 mg once daily
>
> Posaconazole delayed-release tablets 300 mg once daily
>
>
>
> 70 mg once daily
>
> Interrupt dose as recommended per Section 2.2 of the full Prescribing Information
>
>
>
>
> Other strong CYP3A inhibitors<sup>‡</sup>
>
>
>
> Avoid concomitant use. If these inhibitors will be used short-term (such as anti-infectives for 7 days or less), interrupt IMBRUVICA<sup>®</sup>
>
> After discontinuation of a CYP3A inhibitor, resume previous dose of IMBRUVICA<sup>®</sup> per Sections 2.1 and 7.1 of full Prescribing Information.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=dose%20modifications%20for%20CYP3A%20inhibitors,7.1%20of%20full%20Prescribing%20Information.)

> “Examples of moderate CYP3A inhibitors include: aprepitant, ciprofloxacin, conivaptan, crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin,
> fluconazole, fluvoxamine, grapefruit juice, imatinib, isavuconazole, tofisopam, verapamil.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=Examples%20of%20moderate%20CYP3A%20inhibitors,juice%2C%20imatinib%2C%20isavuconazole%2C%20tofisopam%2C%20verapamil.)

> “Examples of strong CYP3A inhibitors include: cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir,
> itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and ombitasvir (and/or dasabuvir), posaconazole, ritonavir, saquinavir and
> ritonavir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=Examples%20of%20strong%20CYP3A%20inhibitors,and%20ritonavir%2C%20telithromycin%2C%20troleandomycin%2C%20voriconazole.)

> “These examples are a guide and not considered a comprehensive list of all possible drugs that may fit these categories.”

Source: [IMBRUVICA: Additional Dosing Info - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/additional-dosing-information#:~:text=These%20examples%20are%20a%20guide,that%20may%20fit%20these%20categories.)

Note: On the page, each coadministered drug group is followed by the Imbruvica dose that applies to it.

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
